Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
4 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.

Ultra rapid lispro as good as lispro in reducing HbA1c

Elaine Soliven
27 Oct 2020

Ultra rapid lispro (URLi) was noninferior to lispro in reducing HbA1c levels in adults with type 1 diabetes (T1D), according to the PRONTO-Pump-2* study presented at EASD 2020. 

“URLi is a novel, prandial, insulin lispro formulation developed to more closely match physiological insulin secretion ... With multiple daily injections (MDIs), URLi has shown superior post-prandial glucose (PPG control) and noninferior HbA1c reduction compared to lispro,” said Dr Mark Warren from Physicians East Professional Association in Greenville, North Carolina, US.

This phase III, double-blind, parallel, active-controlled trial analysed 432 patients with T1D (mean HbA1c 7.55 percent; mean diabetes duration of 25.6 years). Participants were randomized to receive either URLi (n=215; mean age 48.2 years) or lispro (n=217, mean age 44.7 years) administered via CSII** for 16 weeks. The primary endpoint of the study was the change in HbA1c level at 16 weeks. PPG control was assessed with a standardized meal test at randomization and week 16. [EASD 2020, abstract 58]

URLi was noninferior to lispro in terms of HbA1c reduction from baseline to week 16 (from 7.56 to 7.48 percent for URLi and from 7.54 to 7.46 percent for lispro).

Moreover, based on mixed meal tolerance test, URLi demonstrated superiority to lispro in controlling PPG levels at 1-hour (least squares mean [LSM] difference, -1.34 mmol/L; p<0.001) and 2-hour post-meal (LSM difference, -1.54 mmol/L; p<0.001).

The mean post-meal incremental area under the curve (AUC) was significantly reduced by 46 percent from 0–1 hour (0.29 vs 0.54 mmol h/L; p<0.001) and by 37 percent from 0–2 hour (1.03 vs 1.64 mmol h/L; p<0.001) with URLi compared with lispro.

Among patients with hypoglycaemia (<3.0 mmol/L), URLi users spent significantly less time in hypoglycaemia than lispro users during daytime (14.8 vs 19.2 minutes; p=0.029), nighttime (6.82 vs 10.3 minutes; p=0.007), and the 24-hour period (21.7 vs 29.1 minutes; p=0.006).

URLi users also achieved a significantly lower rate of post-meal hypoglycaemia at 2–4 hours (47.2 percent vs 48.9; p=0.041) and ≤4 hours (47.2 percent vs 48.9 percent; p=0.044). “[Of note,] post-meal hypoglycaemia was lower with URLi despite having lower post-prandial blood sugars,” said Warren.

Patients on lispro also had a significantly lower rate of all documented hypoglycaemia (84.4 percent vs 85.6 percent; p=0.049) than those on lispro, while similar rate of nocturnal hyperglycaemia was observed between the two treatment arms (45.8 percent vs 53.4 percent).

Among patients with blood glucose level of <3.9 mmol/L, a significantly reduced time spent in hypoglycaemia was observed with URLi compared with lispro (46.0 vs 54.4 minutes; p=0.028 [daytime], 16.7 vs 23.5 minutes; p=0.002 [nighttime], and 62.9 vs 77.2 minutes; p=0.006 [24-hour period]).

On the other hand, those with blood glucose level of >10.0 and >13.9 mmol/L, a similar time spent in hyperglycaemia was noted across all time points, Warren noted.

However, treatment-emergent adverse events (AEs), particularly infusion site pain and reaction, occurred more frequently in the URLi arm than the lispro arm (60.5 percent vs 44.7 percent), which were mostly mild or moderate in severity. Also, more patients in the URLi arm discontinued study treatment due to AEs than those in the lispro arm (6.0 percent vs 0.9 percent).

“Compared with lispro, when delivered by CSII in patients with T1D, URLi demonstrated noninferior HbA1c reduction, superior PPG control, less [time in] hypoglycaemia, and an acceptable safety profile,” Warren concluded.

“[Of note,] URLi is currently approved for both MDI and CSII (insulin pump) [therapy] in the EU, Japan, and Brazil, and for MID in the US” said Warren.

 

*PRONTO-Pump-2: A study comparing LY900014 to insulin lispro (Humalog) in adults with type 1 diabetes using insulin pump therapy

**CSII: Continuous subcutaneous insulin infusion

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
4 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.